Hunter Land, Vice President of Research and Development at US-based Biopharmaceutical Research Company, has called for the cannabis industry to explore the therapeutic possibilities of the cannabis plant and adopt a more scientific approach to developing medicines. Land urged the industry to move beyond the focus on THC and CBD, stating that there are 148 other cannabinoids that need to be explored. He also criticised the use of the term "strain" and described full spectrum and broad spectrum as ambiguous phrases that create an impression of administering "mystery soup" to patients. Land emphasised the need for the industry to be more specific about the ingredients in cannabis medication and the indications it is targeting. Read more →

Late last week, the U.S. Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. Read more →

After years of delay under the Trump administration, the federal government is preparing to award the first new licenses for cultivating cannabis for scientific research, giving U.S. marijuana operators a crack at entering a business that has been dominated by the University of Mississippi for more than 50 years. Read more →

The DEA is finalizing the effort to increase the number of permitted research-grade marijuana growers after initially receiving guidance from its own administrative law judge in February 2007. Read more →

Last week the US government announced it would begin granting growing approvals to several companies for medicinal marijuana research, ending an informal moratorium on licence issuing which has been in place since the Trump administration. According to a press release from the founder and CEO of Biopharmaceutical Research, George Hodgin, the marijuana manufacturing approvals represent a “monumental step” forward for the American cannabis industry. Read more →

The Drug Enforcement Administration (DEA) on Friday notified several companies that it is moving toward approving their applications to become federally authorized marijuana manufacturers for research purposes. Read more →

The U.S. government has approved new growers of research marijuana for the first time in more than 50 years, people involved in the process said, widening the capacity to study the drug’s medical value. Read more →

Pharmaceutical cannabis: Achieving a consistent product from a highly variable plant “Growing like a weed.” You’ve no doubt heard this phrase before, in reference to the undesirable, relentless pest plants that overtake our gardens. Perhaps not surprisingly, this phrase is also commonly applied to the cannabis plant. Read more →

The U.S. government is expanding the number of businesses that can grow marijuana for federally approved study after years of delay under the Trump administration. Read more →

While saying that this year has been difficult would be an understatement, 2020 seems to be ending on a high note for cannabis enthusiasts. On Wednesday, the U.N. Commission on Narcotic Drugs voted to remove cannabis from the Schedule IV list, which contains highly addictive drugs such as heroin. Read more →